Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10885
Shown on this page
12
Current sort
Recently updated
Location scope
Nashville, TN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Nashville, Tennessee. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 973–984 of 10,885 matching trials in Nashville, TN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Severe Aplastic Anemia
Interventions
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Drug · Procedure · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
ART6043, Olaparib
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more
Conditions
Open Midline Laparotomy
Interventions
Phasix™ Mesh
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 17 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Acute Salt Handling in Orthostatic Intolerance

NCT00581633
Conditions
Postural Tachycardia Syndrome, Orthostatic Tachycardia, Orthostatic Intolerance
Interventions
normal saline (0.9%)
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Results available

Ruxolitinib for Premalignant Breast Disease

NCT02928978
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)

NCT00692471
Conditions
Postural Tachycardia Syndrome, Orthostatic Intolerance, Sleep Disorders
Interventions
Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter
Device
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
Active, not recruiting Not applicable Interventional

Oral Water Ingestion in Heart Transplant Patients

NCT00581321
Conditions
Blood Pressure, Cardiac Transplantation
Interventions
water
Dietary Supplement
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
2
States / cities
Nashville, Tennessee
Conditions
Gastrointestinal Stromal Tumors
Interventions
Ripretinib, Sunitinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
43
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more
Conditions
Primary Sjögren Syndrome
Interventions
RSLV-132, Placebo
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more
Conditions
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Interventions
ML261
Biological
Lead sponsor
Moonlight Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
St Louis, Missouri • Hackensack, New Jersey • New York, New York + 4 more
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee